A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how
well they work compared with standard platinum-based chemotherapy in treating patients with
platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back.
Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian
tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for
tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine
hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate
and olaparib is more effective than standard platinum-based chemotherapy in treating patients
with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.